Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.57 |
| ▸ | CTSE | P14091 | 1/20 | 0.57 |
| ▸ | PGC | P20142 | 1/20 | 0.57 |
| ▸ | REN | P00797 | 12/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6443876 | 1.00 | CTSD (0.57) | CTSDCTSEPGCRENKLK5 | |
| SCHEMBL6445403 | 1.00 | CTSD (0.57) | CTSDCTSEPGCRENKLK5 | |
| SCHEMBL6449191 | 0.92 | CTSD (0.61) | CTSDCTSEPGCRENKLK5 | |
| SCHEMBL6449190 | 0.92 | CTSD (0.61) | CTSDCTSEPGCRENKLK5 | |
| SCHEMBL7408240 | 0.92 | CTSD (0.61) | CTSDCTSEPGCRENKLK5 | |
| SCHEMBL6443284 | 0.86 | PSEN1 (0.52) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6443277 | 0.86 | PSEN1 (0.52) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6442709 | 0.84 | CTSD (0.51) | CTSDCTSEPGCRENKLK5 | |
| SCHEMBL6442715 | 0.84 | CTSD (0.51) | CTSDCTSEPGCRENKLK5 | |
| SCHEMBL6444542 | 0.84 | CTSD (0.51) | CTSDCTSEPGCRENKLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | CTSD 110/4885CTSE 62/4885PGC 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.